Article originalTraitement des carcinoses péritonéales par exérèse complète et chimiohyperthermie intrapéritonéale. Étude de phase I–II permettant de définir la meilleure procédure techniqueTreatment of peritoneal carcinomatosis with complete cytoreductive surgery and intraperitoneal chemohyperthermia (IPCH). A phase I–II study in order to define the best procedure
Références (23)
- et al.
Experimental and clinical status of intraperitoneal chemotherapy
Eur J Cancer
(1990) - et al.
Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination
Surgery
(1996) - et al.
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines
Eur J Cancer
(1998) La chimiothérapie intrapéritonéale immédiate après chirurgie de réduction dans les carcinoses péritonéales: Pourquoi? Pour qui?
Ann Chir
(1995)- et al.
Peritoneal seeding following curative resection of colonic carcinoma: implications for adjuvant therapy
Dis Colon Rectum
(1991) - et al.
Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy
Reg Cancer Treat
(1988) - et al.
Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts
Hepato-Gastroenterol
(1994) - et al.
Tissue concentration of platinum after intraperitoneal cisplatin administration in patients
Cancer cell seeding during abdominal surgery: experimental studies
- et al.
Irrigation does not dislodge or destroy tumor cells adherent to the tumor bed
J Surg Oncol
(1993)
Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis
Dis Colon Rectum
Cited by (41)
Cytoreductive surgery for peritoneal disease: From palliative to curative
2019, Bulletin de l'Academie Nationale de MedecineCan machine learning predict resecability of a peritoneal carcinomatosis?
2019, Surgical OncologyCitation Excerpt :Furthermore, the contraindication for which the addition is equivalent to a major contraindication (obesity, obstruction, malnutrition) [8] exists. HIPEC is performed only for a complete CRS, and a survival benefit is observed [9,10]. Two prognostic resection factors have been identified, the PCI (Peritoneal Cancer Index) defining the extent of the disease before surgery, calculated intraoperatively, and the quality of surgical debulking, as measured by the surgical completeness cytoreduction score (CCs) [11–14].
Institutional experience of cytoreductive surgery with peritonectomy and intraperitoneal chemotherapy for ovarian cancer
2017, Clinica e Investigacion en Ginecologia y ObstetriciaTreatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: State of the art and future developments
2011, Surgical OncologyCitation Excerpt :Jacquet and Sugarbacker reported that, in animal models, an intra-abdominal pressure of 20 and 30 mm Hg increased tissue uptake of doxorubicin in bladder, diaphragm, and abdominal wall during the first 10 min of intraperitoneal administration [48]. Elias and colleagues [49] did a prospective phase II trial testing seven different HIPEC techniques in 32 patients. They found that complete closure of the abdominal wall before the perfusion restricted the volume of the perfusion, decreased spatial diffusion of the instillate, and resulted in lack of thermal homogeneity.
Using a heating cable within the abdomen to make hyperthermic intraperitoneal chemotherapy easier: Feasibility and safety study in a pig model
2010, European Journal of Surgical Oncology